₹ 2,327.90
-40.90 (-1.73%)
268
52.63% Buy (Based on 19 analysts)M
Mankind Pharma
₹ 2,327.90
26852.63% Buy (Based on 19 analysts)Mankind Pharma Share Price Today
Today Mankind Pharma opened at 2,366.50 while its previous close was at 2,368.80. In todays trading session MANKIND reached a high of 2,390.00 and low of 2,317.00. The average traded price for today is 2,340.79. The 50 DMA stands at 2,468.18 and 200 DMA is at 2,279.26. Looking at intraday trend, the stock is in Downtrend.
Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.
MANKIND Stock Performance
Markets Today
High
2,390.00
Low
2,317.00
Open at
2,366.50
Prev Close
2,368.80
Volumes
1,22,389
Avg Price
2,340.79
Lower Circuit
2,095.20
Upper Circuit
2,560.60
Last Traded Details
Quantity
1
Time
15:56:50
Price Movement
Historical Performance
3 M High
2,642.00
3 M Low
2,285.10
1 Yr High
2,674.00
1 Yr Low
1,909.70
3 Yr High
3,054.80
3 Yr Low
1,683.05
5 Yr High
3,054.80
5 Yr Low
1,242.00
1-Year Performance
MANKIND Pros and Cons
Consolidated revenue grows from ₹3,443 Cr in Q4 FY26 to ₹4,031 Cr in Q1 FY27, driven by strong domestic and export demand
Net debt falls from ₹5,249 Cr in Q1 FY26 to ₹3,377 Cr in Q1 FY27, improving the debt-to-EBITDA ratio to 0.9x
EBITDA margin expands from 23.8% in Q1 FY26 to 26.3% in Q1 FY27, reflecting effective cost control and pricing power
Export revenue climbs from ₹469 Cr in Q1 FY26 to ₹605 Cr in Q1 FY27, maintaining a steady 15% share of total sales
Consumer healthcare digital share grows from 11% in Q1 FY26 to 15% in Q1 FY27, signaling successful omnichannel penetration
Working capital days with the BSV acquisition rise from 46 in Q2 FY26 to 52 in Q1 FY27, indicating integration-related cash cycle pressure
Anti-diabetic outperformance declines from 1.6x in Q1 FY26 to 1.1x in Q1 FY27, suggesting a moderating competitive edge in the segment
Cardiac outperformance falls from 1.5x in Q1 FY26 to 1.1x in Q1 FY27, reflecting narrowing growth lead against peers
Consumer healthcare EBITDA margin eases from 21.4% in Q4 FY26 to 18.6% in Q1 FY27, pointing to seasonal volume mix shifts
MANKIND Analyst Rating
Buy
Analysts have suggested that investors can
Buy this Stock
- By Refinitiv from 19 analysts
Buy
52.63%
Hold
26.32%
Sell
21.05%
Get forecast for Price, ROA & ROE based on analyst ratings.
MANKIND Latest News
MANKIND Share Price History
MANKIND Fundamentals
Company Valuation
Market Cap (₹ Cr.)
96,141
PE Ratio
46.80
PB Ratio
5.94
Dividend Yield
0.04%
ROE
11.70%
ROCE
13.78%
Book Value (₹)
394.64
Face Value (₹)
1.00
Analyse MANKIND with 12+ custom fundamentals and financial ratios.
Share Holding Pattern
| Held By | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 72.68% | 72.67% | 72.66% | 72.66% | 72.63% |
| Domestic Institutional Investors (DII) | 11.50% | 11.92% | 13.25% | 14.46% | 15.39% |
| Foreign Institutional Investors (FII) | 13.07% | 12.84% | 11.34% | 10.24% | 9.45% |
| Public Investors | 1.52% | 1.36% | 1.52% | 1.39% | 1.29% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Promoters
Domestic Institutional Investors (DII)
Foreign Institutional Investors (FII)
Public Investors
Government
Mankind Pharma Return Calculator
Note: Past profits do not guarantee future returns.
MANKIND Investment Returns
Short Term
1 Week
1 Month
3 Months
6 Months
9 Months
Long Term
1 Year
2 Years
3 Years
4 Years
5 Years
- In Short Term
- In Long term
1 Week
1 Month
3 Months
6 Months
9 Months
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
MANKIND Technicals
Moving Averages
Technical Indicators
Summary of Technical Indicators for MANKIND
Margin on MANKIND
*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).
MANKIND Financials Summary
In Crores
MANKIND Financials
Income Statement
In Cr
Balance Sheet
In Cr
Cash Flow
In Cr
Corporate Actions
| Date | Corporate Action | Information |
|---|---|---|
| 30th Jul 2026, Thursday |  Stock Result | Q1 FY 26-27 Results  |
| 19th May 2026, Tuesday | Stock Result | Q4 FY 26-27 Results |
| 3rd Feb 2026, Tuesday | Stock Result | Q3 FY 25-26 Results |
| 6th Nov 2025, Thursday | Stock Result | Q2 FY 25-26 Results |
| 8th Aug 2025, Friday |  Dividend | Interim Dividend of ₹1/share |
The above dates are ex-dates.
Check MANKIND latest Company Filings, Investor Presentation & Conference Call details.
MANKIND Revenue Growth
All values are in Crores
Revenue
Profit
Loss
| Financial Year | Revenue | Revenue Growth | Net Profit | Profit Growth |
|---|---|---|---|---|
| FY 2025-26 | 10,747 | 7.46% | 2,038 | 14.09% |
| FY 2024-25 | 10,001 | 12.37% | 1,725 | -4.81% |
| FY 2023-24 | 8,900 | 7.36% | 1,773 | 50.3% |
MANKIND Options Snapshot
MANKIND Futures Snapshot
Use from 12+ Pre-built Strategies or Build Your Own to trade MANKIND FnO contracts.
Top Mutual Funds Invested in MANKIND
MANKIND Popular Brands
MANKIND Similar Stocks
NSE Indices Today
Open IPOs
What's New In The Market
FAQs on MANKIND
What is the share price of Mankind Pharma?
What is the 52W high and 52W low of Mankind Pharma?
What is the return on Mankind Pharma share?
- Past 1 year: -9.03%
- Past 3 years: 35.62%
- Past 5 years: 66.28%
What is the PE and PB Ratio of Mankind Pharma?
What is the EPS of Mankind Pharma?
What is the shareholding pattern of Mankind Pharma?
- DIIs - 15.39%
- FII - 9.45%
- Promoters - 72.63%
- Public Investors 1.29%
- Goverenment - 0.00%
How to buy Mankind Pharma shares online?
How to buy Mankind Pharma shares on Dhan?
- Download the Dhan App to Open a Demat Account
- Navigate to the “Money Tab”
- Add money to your account
- Search for Mankind Pharma share
- Tap on “Buy”
